| Literature DB >> 19337409 |
Montserrat Colilla1, Miguel Manzano, María Vallet-Regí.
Abstract
Research in the development of new bioceramics with local drug delivery capability for bone regeneration technologies is receiving great interest by the scientific biomedical community. Among bioceramics, silica-based ordered mesoporous materials are excellent candidates as bone implants due to two main reasons: first, the bioactive behavior of such materials in contact with simulated body fluids, ie, a carbonate hydroxyapatite similar to the mineral phase of bone is formed onto the materials surfaces. Second, their capability of acting as delivery systems of a large variety of biologically active molecules, including drugs to treat bone infection, inflammation or diseases, and molecules that promote bone tissue regeneration, such as peptides, proteins, growth factors, and other osteogenic agents. The recent chemical and technological advances in the nanometer scale has allowed the design of mesoporous silicas with tailored structural and textural properties aimed at achieving a better control over molecule loading and release kinetics. Moreover organic modification of mesoporous silica walls has been revealed as a key strategy to modulate molecule adsorption and delivery rates.Entities:
Keywords: bone tissue regeneration; controlled delivery systems; silica-based ordered mesoporous materials
Mesh:
Substances:
Year: 2008 PMID: 19337409 PMCID: PMC2636592 DOI: 10.2147/ijn.s3548
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Schematic representation of liquid crystal mechanism used to describe the synthesis of silica-based ordered mesoporous materials.
Mesopore diameters of MCM-41 matrices obtained using surfactants with different chain lengths and ibuprofen release after 24 hours of assay. After 48 hours of test, all ibuprofen was released from C12TAB and C16TAB matrices; on the other hand, after 55 hours of assay, ibuprofen release was not completed for 85%C8TAB-15%C10TAB and 70%C8TAB-30%C10TAB
| Surfactant* | Pore diameter (nm) | Ibuprofen released after 24 h (%) |
|---|---|---|
| 85%C8TAB-15%C10TAB | 2.5 | 41 |
| 70%C8TAB-30%C10TAB | 2.7 | 42 |
| C12TAB | 3.3 | 49 |
| C16TAB | 3.6 | 61 |
Abbreviations: C8TAB, octyltrimethylamonium bromide; C10TAB, decyltri-methylamonium bromide; C12TAB, dodecyltrimethylamonium bromide; C16TAB, hexadecyltrimethylamonium bromide.
Figure 2Schematic representation of the structure of different proteins with diverse dimensions (RCSB 2008) compared to thiol-functionalized SBA-15.
Figure 3a) Effect of hydrothermal treatment on SBA-15 mesopore diameter. b) BSA loading into SBA-15 mesoporous matrices with different pore diameter. c)Table showing the BSA loading on functionalized matrices with different pore diameters. d) Release profiles of BSA from unmodified and amino-modified matrices.
Figure 4Dependence of ibuprofen loading on surface area of MCM-41 mesoporous materials synthesized using diverse cationic surfactants with different length-chains. The surfactants and the percentage employed are also displayed (See footnote on Table 1).
Alendronate loading and release data from MCM-41 and SBA-15 before and after functionalization with amino groups
| Material | Surface area, SBET (m2/g) | Alendronate loaded (%) | Alendronate released after 24 h (%) | Total delivery time (h) |
|---|---|---|---|---|
| MCM-41 | 1157 | 14 | 58 | 72 |
| MCM-41-NH2 | 782 | 37 | 28 | 264 |
| SBA-15 | 719 | 8 | 55 | 264 |
| SBA-15-NH2 | 385 | 22 | 11 | 264 |
Notes: Incomplete delivery (76%),
Incomplete delivery (69%).
Figure 5Alendronate adsorption on MCM-41 and SBA-15 mesoporous materials before and after functionalization with amino groups.
Figure 6TEM images of MCM-41, SBA-15, and MCF mesoporous materials. Their corresponding nitrogen adsorption isotherms and pore size distributions are also displayed.
BSA loading and release data from SBA-15 and MCF materials before and after functionalization with amino groups
| Material | Pore diameter (nm) | Surface area, SBET (m2/g) | Pore volume (cm3/g) | BSA loaded (%) | BSA released after 24 h (%) | Total % of BSA released after 264 h of assay |
|---|---|---|---|---|---|---|
| SBA-15 | 8.5 | 874 | 1.1 | 20 | 74 | 93 |
| SBA-15-NH2 | 6.9 | 348 | 0.7 | 21 | 27 | 87 |
| MCF | 17.9 | 452 | 1.9 | 24 | 62 | 90 |
| MCF-NH2 | 15.7 | 275 | 1.6 | 27 | 22 | 86 |
Notes: The pore diameter corresponds to the size of the windows present in the spherical cells.
Figure 7a) Amount of BSA loaded (%) and b) BSA delivery profiles for SBA-15 and MCF mesoporous matrices before and after functionalization using amino groups.